Genmab to buy back 370,000 shares

The biotech firm has initiated a share buy-back program to mitigate dilution from warrants.

Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab

A total of 370,000 Genmab shares will be repurchased by the biotech firm itself, according to a company press release.

A new share buy-back program aims to mitigate dilution of shares from warrant exercises, the firm writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs